223 reactions · 198 shares | This week, Pfizer reported some encouraging early results from Phase 3 of its COVID-19 vaccine clinical trials. Dr. Josh Sharfstein, former principal deputy commissioner for the U.S. Food and Drug Administration, talks about some possible next steps, such as how this vaccine—or others—could be made available, and when. | Johns Hopkins Bloomberg School of Public Health | Facebook